Cencora, Inc. $COR Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its position in shares of Cencora, Inc. (NYSE:COR) by 31.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,516 shares of the company’s stock after selling 109,505 shares during the period. Assenagon Asset Management S.A. owned about 0.13% of Cencora worth $82,248,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at $30,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares in the last quarter. Cloud Capital Management LLC acquired a new position in shares of Cencora during the third quarter worth $31,000. Caitlin John LLC purchased a new position in Cencora in the third quarter valued at $31,000. Finally, Westside Investment Management Inc. raised its stake in Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The acquisition expands Cencora’s Retina Consultants of America platform and strengthens its footprint in the fast-growing eye care market, adding scale and potential cross-selling opportunities for pharma and services. Cencora to buy EyeSouth’s retina business for $1.1 billion
• Positive Sentiment: Analyst and trade coverage frames the deal as a clear add-on to RCA that builds scale in a specialty with high procedure volumes and recurring treatment needs, which could support revenue and margin improvement over time. COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal
• Neutral Sentiment: The transaction is widely reported across outlets (Reuters, Seeking Alpha, Fierce Healthcare), which helps transparency and may accelerate investor re-pricing; details on financing and expected contribution to guidance remain limited. Cencora to buy retina business of EyeSouth Partners for $1.1 billion
• Neutral Sentiment: COR is included in actively managed ETF baskets highlighted by MarketBeat, which can bring incremental demand from fund flows rather than direct company fundamentals. That placement may amplify moves in COR shares as funds trade. Active ETFs Surge Past Passive, and These Are in the Lead (COR)
• Negative Sentiment: Potential near-term negatives include transaction financing, integration costs and execution risk; Cencora already carries a relatively high debt-to-equity ratio, so investors should watch how the deal is funded and whether it materially affects leverage. Conshohocken’s Cencora Prepares for Leadership Change This Summer

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on COR shares. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Robert W. Baird set a $415.00 target price on Cencora in a research report on Tuesday, January 13th. JPMorgan Chase & Co. boosted their target price on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $403.17.

Cencora Stock Performance

Shares of COR stock opened at $327.12 on Wednesday. The stock’s 50-day moving average is $354.13 and its two-hundred day moving average is $340.68. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 1 year low of $265.59 and a 1 year high of $377.54. The firm has a market cap of $63.63 billion, a price-to-earnings ratio of 39.32, a PEG ratio of 1.49 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the business earned $3.73 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is currently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.